

## **Joint Research Commences Between Yamaguchi University and Hitachi, Ltd. on CAR-T Cell Technology Improvement Using CAR Sequences Provided by Noile-Immune**

Noile-Immune Biotech Inc. (hereinafter “Noile-Immune”) hereby announces that Noile-Immune will provide CAR sequences and cooperate in the joint research project between Yamaguchi University, a research partner of Noile-Immune, and Hitachi Ltd., on CAR-T cell technology improvement, as Yamaguchi University announced its commencement on December 16, 2025 (Reference 1).

Noile-Immune’s President & CEO, Koji Tamada, MD, Ph.D. (Professor, Department of Immunology, Yamaguchi University Graduate School of Medicine; Director, Research Institute for Cell Design Medical Science, Yamaguchi University) and Noile-Immune’s Adviser, Yukimi Sakoda, M.D., Ph.D. (Associate Professor, Department of Immunology, Yamaguchi University Graduate School of Medicine) will participate in this joint research. The CAR sequence plays a crucial role to recognize and attack cancer cells in CAR-T cell therapy. In this joint research, based on the CAR sequence provided by Noile-Immune, the optimized CAR-T cell design and screening will be conducted. As this joint research progresses, Noile-Immune’s PRIME CAR-T cell, which are currently under development, will be optimized, and as a result, it is expected to improve the safety and efficacy of the development pipelines, increase the likelihood of launch and practical application, and enhance the overall value of the pipelines.

Noile-Immune is committed to research and development with the goal of delivering the latest cancer immunotherapy as a new treatment option for patients suffering from cancer worldwide.

(Reference 1) Source: Yamaguchi University, Press release issued on December 16, 2025, URL: <https://www.yamaguchi-u.ac.jp/wp-content/uploads/2025/12/25121601.pdf>

### **【Noile-Immune Biotech Inc.】**

Noile-Immune Biotech Inc. (TSE: 4893) is a biotech company, an academia start-up, and is committed to the practical application of next-generation immunotherapy for solid cancers by utilizing PRIME CAR-T cells which incorporate Noile-Immune's proprietary PRIME technology, an innovative approach to enhance the therapeutic effects of immune cell therapy. As PRIME technology can be combined with various chimeric antigen receptors (CARs) to create novel drugs and applied to a broad range of modalities, it is expected to develop many anti-cancer therapeutic approaches in combination with other technologies in the future. Through our business activities, Noile-Immune aims to contribute to the creation of a society that can overcome cancer.

For more information, please visit <https://www.noile-immune.com/en.html>.

Contact for inquiries or additional information

2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan

Noile-Immune Biotech Inc.

[pr@noile-immune.com](mailto:pr@noile-immune.com)